Valuation: Addex Therapeutics Ltd

Market Cap 4.18M 5.21M 4.46M 3.82M 7.17M 499M 7.27M 49.34M 19.24M 250M 19.56M 19.14M 828M P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 2.57M 3.21M 2.75M 2.35M 4.42M 307M 4.48M 30.39M 11.85M 154M 12.05M 11.79M 510M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 day-15.46%
1 week-10.71%
Current month-16.67%
1 month-12.50%
3 months-22.22%
6 months-27.08%
Current year-36.82%
1 week 0.03
Extreme 0.031
0.07
1 month 0.03
Extreme 0.031
0.07
Current year 0.03
Extreme 0.031
0.07
1 year 0.03
Extreme 0.031
0.08
3 years 0.03
Extreme 0.031
0.26
5 years 0.03
Extreme 0.031
1.63
10 years 0.03
Extreme 0.031
4
Manager TitleAgeSince
Chief Executive Officer 58 01/06/2013
Director of Finance/CFO 40 01/06/2017
Chief Tech/Sci/R&D Officer 69 28/11/2016
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 01/01/2015
Director/Board Member 81 12/05/2010
Date Insider Type Main position Quantity % Market Cap.
18/03/26 Other

HEAD OF TRANSLATIONAL SCIENCE

506,765 0.2318%
18/03/26 Other

Director

269,561 0.1233%
Change 5-day change 1-year change 3-year change Capi.($)
-15.46%-10.71%-36.36%-60.67% 5.21M
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average -1.14%+2.92%+72.73%+107.27% 27.65B
Weighted average by Cap. +0.48%+4.72%+102.56%+148.52%

Financials

2024 2025
Net sales 410K 512K 438K 375K 704K 48.95M 714K 4.84M 1.89M 24.59M 1.92M 1.88M 81.33M 173K 216K 185K 158K 297K 20.64M 301K 2.04M 796K 10.37M 810K 792K 34.29M
Net income 7.06M 8.8M 7.54M 6.46M 12.12M 842M 12.28M 83.36M 32.51M 423M 33.06M 32.34M 1.4B -6.73M -8.39M -7.19M -6.16M -11.56M -803M -11.71M -79.49M -31M -403M -31.52M -30.83M -1.33B
Net Debt -3.3M -4.12M -3.53M -3.02M -5.67M -394M -5.74M -38.99M -15.2M -198M -15.46M -15.12M -654M -1.6M -2M -1.71M -1.47M -2.76M -191M -2.79M -18.95M -7.39M -96.18M -7.51M -7.35M -318M
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
21/08/26 CHF 0.0350 -15.46% 15,284,635
20/08/26 CHF 0.0414 +1.97% 35,187
19/08/26 CHF 0.0406 -1.93% 17,841
18/08/26 CHF 0.0414 +1.47% 3,530
17/08/26 CHF 0.0408 +4.08% 32,576
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADXN Stock